Prevention of hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis by pegylated IFN-alpha-2a after surgical resection or radiofrequency ablation

Prevention of hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis by pegylated IFN-alpha-2a after surgical resection or radiofrequency ablation - GLSG.2004.Pegasys

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000203

Enrollment

100

Registered

2005-09-13

Start date

2003-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C,cirrhosis,hepatocellular carcinoma

Interventions

PEG-IFN-alpha2a no treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HCV-RNA(+) hepatocarcinoma Child-Pugh A 3months after HCC treatment

Exclusion criteria

Exclusion criteria: ANC<750/mm3,Plt<50,000/mm3 Child-Pugh B,C

Design outcomes

Primary

Measure	Time frame
Prevention of hepatocellular carcinoma	—

Secondary

Measure	Time frame
HCV-RNA,ALT,fibrosis	—

Countries

Japan

Contacts

Public ContactKen Sato

Gunma University Graduate School of Medicine Department of Medicine and Molecular Science

satoken@gunma-u.ac.jp027-220-8127

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026